Atsena Therapeutics reposted this
👀📢 October's FDA Roundup is here... Catch up on latest announcements and approvals from the FDA concerning #Ophthalmology. ◾ Clobetasol: Post-Operative Inflammation and Pain Following Ocular Surgery - Eyenovia, Inc., Michael Rowe ◾ATSN-201: X-Linked Retinoschisis - Atsena Therapeutics, Patrick Ritschel ◾Triesence: Visualization During Vitrectomy and Ocular Inflammatory Conditions - Harrow ◾Alcaftadine Ophthalmic Solution: Itchy Eyes - Alembic Pharmaceuticals Limited ◾MCO-010: Retinitis Pigmentosa - Nanoscope Therapeutics Inc. ◾CLS-AX: Neovascular Age-Related Macular Degeneration - Clearside Biomedical, Inc. ◾OcuCool: Cooling Anesthetic Device - Recens Medical US Read the full article here ➡: https://bit.ly/3MeeGJn --------------------------- #Ophthalmology #Ophthalmologist #EyeHealth #EyeCare #EyeDoctor #EyeCareProfessional #Clobetasol #EyeDrops #OcularInflammation #EyeSurgery #EyeSurgeon #OcularSurgery #OphthalmicSteroid #Pharmaceuticals #ATSN201 #XLinkedRetinoschisis #XLRS #OrphanDrug #RarePediatricDisease #OcularGeneTherapy #GeneTherapy #RetinalDisease #Triesence #Vitrectomy #Corticosteroid #Alcaftadine #OphthalmicSolution #ItchyEyes #MCO010 #RetinitisPigmentosa #BiologicsLicenseApplication #CLSAX #ClinicalTrials #WetAMD #nAMD #AgeRelatedMacularDegeneration #ODYSSEY #NCT05891548 #VisualAcuity #OcuCool #Ocularsurface #MedicalAnesthetics